TCI Wealth Advisors’s BridgeBio Pharma BBIO Stock Holding History

TCI Wealth Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-632	Closed	-$10.5K	–	416
2023 Q1	$10.5K	Buy	632 +184	+41%	+$2.15K	﹤0.01%	1062
2022 Q4	$3.41K	Sell	448 -1	-0.2%	-$10	﹤0.01%	1781
2022 Q3	$4K	Buy	449 +1	+0.2%	+$10	﹤0.01%	1569
2022 Q2	$4K	Buy	+448	New	+$3.75K	﹤0.01%	1589
2021 Q4	–	Sell	-151	Closed	-$7K	–	2304
2021 Q3	$7K	Hold	151	–	–	﹤0.01%	1331
2021 Q2	$9K	Buy	151 +70	+86%	+$4K	﹤0.01%	1012
2021 Q1	$5K	Buy	+81	New	+$5.3K	﹤0.01%	1221
2020 Q1	–	Sell	-28	Closed	-$1K	–	1477
2019 Q4	$1K	Buy	+28	New	+$776	﹤0.01%	1284

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

TCI Wealth Advisors's BBIO Position: Q2 2023 in Review

TCI Wealth Advisors sold out of BridgeBio Pharma (BBIO) in Q2 2023, closing a stake of 632 shares — an estimated $10.5K sold.

TCI Wealth Advisors first reported a position in BBIO in Q4 2019 and held it in 8 quarters. The position peaked at $10.5K in Q1 2023. 197 funds tracked by Wall St. Rank hold BBIO as of Q2 2023.

TCI Wealth Advisors reported no remaining BridgeBio Pharma position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 632 BridgeBio Pharma shares in Q2 2023, an estimated $10.5K.
TCI Wealth Advisors first reported a position in BridgeBio Pharma in Q4 2019 and held it in 8 quarters.
TCI Wealth Advisors's BridgeBio Pharma position peaked at $10.5K in Q1 2023.
197 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.